JP2013523656A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013523656A5 JP2013523656A5 JP2013501523A JP2013501523A JP2013523656A5 JP 2013523656 A5 JP2013523656 A5 JP 2013523656A5 JP 2013501523 A JP2013501523 A JP 2013501523A JP 2013501523 A JP2013501523 A JP 2013501523A JP 2013523656 A5 JP2013523656 A5 JP 2013523656A5
- Authority
- JP
- Japan
- Prior art keywords
- hcc
- combination
- composition
- nanoparticles
- taxane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 37
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 37
- 239000000203 mixture Substances 0.000 claims description 23
- 239000003795 chemical substances by application Substances 0.000 claims description 17
- 239000002105 nanoparticle Substances 0.000 claims description 16
- 229940123237 Taxane Drugs 0.000 claims description 12
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims description 12
- 102100027211 Albumin Human genes 0.000 claims description 10
- 108010088751 Albumins Proteins 0.000 claims description 10
- 101000831940 Homo sapiens Stathmin Proteins 0.000 claims description 6
- 108091022875 Microtubule Proteins 0.000 claims description 6
- 102000029749 Microtubule Human genes 0.000 claims description 6
- 102100024237 Stathmin Human genes 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 210000004688 microtubule Anatomy 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 5
- 230000015556 catabolic process Effects 0.000 claims description 4
- 238000006731 degradation reaction Methods 0.000 claims description 4
- 102100028247 Abl interactor 1 Human genes 0.000 claims description 2
- 108010040168 Bcl-2-Like Protein 11 Proteins 0.000 claims description 2
- 102000001765 Bcl-2-Like Protein 11 Human genes 0.000 claims description 2
- 102000017925 CHRM3 Human genes 0.000 claims description 2
- 102100040750 CUB and sushi domain-containing protein 1 Human genes 0.000 claims description 2
- 102100033592 Calponin-3 Human genes 0.000 claims description 2
- 102000011068 Cdc42 Human genes 0.000 claims description 2
- 102100028633 Cdc42-interacting protein 4 Human genes 0.000 claims description 2
- 102100024351 Dedicator of cytokinesis protein 7 Human genes 0.000 claims description 2
- 102100031477 Dolichyl-diphosphooligosaccharide-protein glycosyltransferase 48 kDa subunit Human genes 0.000 claims description 2
- 101710167313 Drebrin-like protein Proteins 0.000 claims description 2
- 102100028570 Drebrin-like protein Human genes 0.000 claims description 2
- -1 ERLF1 Proteins 0.000 claims description 2
- 102100036825 Erythroid membrane-associated protein Human genes 0.000 claims description 2
- 102100027421 Heat shock cognate 71 kDa protein Human genes 0.000 claims description 2
- 102100021453 Histone deacetylase 5 Human genes 0.000 claims description 2
- 102100035042 Histone-lysine N-methyltransferase EHMT2 Human genes 0.000 claims description 2
- 101000724225 Homo sapiens Abl interactor 1 Proteins 0.000 claims description 2
- 101000892017 Homo sapiens CUB and sushi domain-containing protein 1 Proteins 0.000 claims description 2
- 101000945410 Homo sapiens Calponin-3 Proteins 0.000 claims description 2
- 101000766830 Homo sapiens Cdc42-interacting protein 4 Proteins 0.000 claims description 2
- 101001052952 Homo sapiens Dedicator of cytokinesis protein 7 Proteins 0.000 claims description 2
- 101001130785 Homo sapiens Dolichyl-diphosphooligosaccharide-protein glycosyltransferase 48 kDa subunit Proteins 0.000 claims description 2
- 101000851733 Homo sapiens Erythroid membrane-associated protein Proteins 0.000 claims description 2
- 101001080568 Homo sapiens Heat shock cognate 71 kDa protein Proteins 0.000 claims description 2
- 101000899255 Homo sapiens Histone deacetylase 5 Proteins 0.000 claims description 2
- 101000877312 Homo sapiens Histone-lysine N-methyltransferase EHMT2 Proteins 0.000 claims description 2
- 101000923835 Homo sapiens Low density lipoprotein receptor adapter protein 1 Proteins 0.000 claims description 2
- 101000928919 Homo sapiens Muscarinic acetylcholine receptor M3 Proteins 0.000 claims description 2
- 101000597499 Homo sapiens Obg-like ATPase 1 Proteins 0.000 claims description 2
- 101000596046 Homo sapiens Plastin-2 Proteins 0.000 claims description 2
- 101000877404 Homo sapiens Protein enabled homolog Proteins 0.000 claims description 2
- 101000983130 Homo sapiens Protein kinase C and casein kinase substrate in neurons protein 2 Proteins 0.000 claims description 2
- 101000615238 Homo sapiens Proto-oncogene DBL Proteins 0.000 claims description 2
- 101100078258 Homo sapiens RUNX1T1 gene Proteins 0.000 claims description 2
- 101001130509 Homo sapiens Ras GTPase-activating protein 1 Proteins 0.000 claims description 2
- 101001106403 Homo sapiens Rho GTPase-activating protein 4 Proteins 0.000 claims description 2
- 101000697510 Homo sapiens Stathmin-2 Proteins 0.000 claims description 2
- 101000762938 Homo sapiens TOX high mobility group box family member 4 Proteins 0.000 claims description 2
- 101000713585 Homo sapiens Tubulin beta-4A chain Proteins 0.000 claims description 2
- 102100034389 Low density lipoprotein receptor adapter protein 1 Human genes 0.000 claims description 2
- 102100035415 Obg-like ATPase 1 Human genes 0.000 claims description 2
- 229930012538 Paclitaxel Natural products 0.000 claims description 2
- 102100035182 Plastin-2 Human genes 0.000 claims description 2
- 102100024952 Protein CBFA2T1 Human genes 0.000 claims description 2
- 102100035093 Protein enabled homolog Human genes 0.000 claims description 2
- 102100026843 Protein kinase C and casein kinase substrate in neurons protein 2 Human genes 0.000 claims description 2
- 102100021384 Proto-oncogene DBL Human genes 0.000 claims description 2
- 108700040655 RUNX1 Translocation Partner 1 Proteins 0.000 claims description 2
- 102100031426 Ras GTPase-activating protein 1 Human genes 0.000 claims description 2
- 102100021431 Rho GTPase-activating protein 4 Human genes 0.000 claims description 2
- 108020004459 Small interfering RNA Proteins 0.000 claims description 2
- 102100028051 Stathmin-2 Human genes 0.000 claims description 2
- 108010040632 Transforming Protein 2 Src Homology 2 Domain-Containing Proteins 0.000 claims description 2
- 102000002016 Transforming Protein 2 Src Homology 2 Domain-Containing Human genes 0.000 claims description 2
- 102000004243 Tubulin Human genes 0.000 claims description 2
- 108090000704 Tubulin Proteins 0.000 claims description 2
- 102100036788 Tubulin beta-4A chain Human genes 0.000 claims description 2
- 238000011374 additional therapy Methods 0.000 claims description 2
- 108010051348 cdc42 GTP-Binding Protein Proteins 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 230000001394 metastastic effect Effects 0.000 claims description 2
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 2
- 238000009099 neoadjuvant therapy Methods 0.000 claims description 2
- 230000000683 nonmetastatic effect Effects 0.000 claims description 2
- 229960001592 paclitaxel Drugs 0.000 claims description 2
- 230000000306 recurrent effect Effects 0.000 claims description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 2
- 206010027761 Mixed hepatocellular cholangiocarcinoma Diseases 0.000 claims 1
- 208000011588 combined hepatocellular carcinoma and cholangiocarcinoma Diseases 0.000 claims 1
- 238000001361 intraarterial administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 210000003240 portal vein Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 description 23
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31815310P | 2010-03-26 | 2010-03-26 | |
| US61/318,153 | 2010-03-26 | ||
| PCT/US2011/030037 WO2011119988A1 (en) | 2010-03-26 | 2011-03-25 | Methods of treatment of hepatocellular carcinoma |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015091142A Division JP2015134825A (ja) | 2010-03-26 | 2015-04-28 | 肝細胞がんの処置方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013523656A JP2013523656A (ja) | 2013-06-17 |
| JP2013523656A5 true JP2013523656A5 (https=) | 2014-05-08 |
| JP5847156B2 JP5847156B2 (ja) | 2016-01-20 |
Family
ID=44673662
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013501523A Active JP5847156B2 (ja) | 2010-03-26 | 2011-03-25 | 肝細胞がんの処置方法 |
| JP2015091142A Pending JP2015134825A (ja) | 2010-03-26 | 2015-04-28 | 肝細胞がんの処置方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015091142A Pending JP2015134825A (ja) | 2010-03-26 | 2015-04-28 | 肝細胞がんの処置方法 |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US9370494B2 (https=) |
| EP (2) | EP2552438B1 (https=) |
| JP (2) | JP5847156B2 (https=) |
| KR (1) | KR101786142B1 (https=) |
| CN (2) | CN103052385B (https=) |
| AU (1) | AU2011230512B2 (https=) |
| BR (1) | BR112012024349A2 (https=) |
| CA (2) | CA3051495A1 (https=) |
| DK (1) | DK2552438T3 (https=) |
| ES (2) | ES2675212T3 (https=) |
| HR (1) | HRP20160609T1 (https=) |
| HU (1) | HUE027749T2 (https=) |
| IL (2) | IL221886A (https=) |
| LT (1) | LT2552438T (https=) |
| MX (2) | MX359413B (https=) |
| NZ (1) | NZ602382A (https=) |
| PL (1) | PL2552438T3 (https=) |
| PT (1) | PT2552438T (https=) |
| TW (1) | TWI495467B (https=) |
| WO (1) | WO2011119988A1 (https=) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| CN103405405A (zh) | 2002-12-09 | 2013-11-27 | 阿布拉西斯生物科学有限责任公司 | 组合物和传递药剂的方法 |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| SI1853250T1 (sl) | 2005-02-18 | 2012-01-31 | Abraxis Bioscience Llc | Kombinacije in reĹľimi dajanja terapevtskih sredstev in kombinirana terapija |
| KR101420445B1 (ko) * | 2005-08-31 | 2014-07-16 | 아브락시스 바이오사이언스, 엘엘씨 | 수 난용성 제약학적 약제 및 항균제를 포함하는 조성물 |
| EP3470071A1 (en) | 2006-12-14 | 2019-04-17 | Abraxis BioScience, LLC | Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane |
| WO2008109163A1 (en) * | 2007-03-07 | 2008-09-12 | Abraxis Bioscience, Llc. | Nanoparticle comprising rapamycin and albumin as anticancer agent |
| JP5579057B2 (ja) * | 2007-06-01 | 2014-08-27 | アブラクシス バイオサイエンス， エルエルシー | 再発性癌の処置のための方法および組成物 |
| HRP20192259T1 (hr) | 2009-04-15 | 2020-03-06 | Abraxis Bioscience, Llc | Pripravci nanočestica bez priona i metode njihove proizvodnje |
| CA3051495A1 (en) | 2010-03-26 | 2011-09-29 | Abraxis Bioscience, Llc | Use of nanoparticles comprising a taxane and albumin in the treatment of hepatocellular carcinoma |
| KR20130028727A (ko) | 2010-03-29 | 2013-03-19 | 아브락시스 바이오사이언스, 엘엘씨 | 치료제의 약물 전달 및 유효성 향상 방법 |
| NZ717490A (en) | 2010-03-29 | 2017-12-22 | Abraxis Bioscience Llc | Methods of treating cancer |
| BR112012030909A2 (pt) | 2010-06-04 | 2020-08-18 | Abraxis Bioscience, Llc | métodos de tratamento de câncer pancreático |
| JP6038123B2 (ja) | 2011-04-28 | 2016-12-07 | アブラクシス バイオサイエンス， エルエルシー | ナノ粒子組成物の脈管内送達およびそれらの使用 |
| JP6216721B2 (ja) | 2011-12-14 | 2017-10-18 | アブラクシス バイオサイエンス， エルエルシー | 粒子を凍結乾燥または凍結するためのポリマー賦形剤の使用 |
| US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
| US20140186447A1 (en) * | 2012-12-28 | 2014-07-03 | Abraxis Bioscience, Llc | Nanoparticle compositions of albumin and paclitaxel |
| US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| EP3698784A1 (en) | 2013-03-12 | 2020-08-26 | Abraxis BioScience, LLC | Methods of treating lung cancer |
| EP2968191B1 (en) | 2013-03-14 | 2021-06-16 | Abraxis BioScience, LLC | Methods of treating bladder cancer |
| JP6387400B2 (ja) | 2013-05-30 | 2018-09-05 | ナノビオティックスＮａｎｏｂｉｏｔｉｘ | 医薬組成物、その製造および使用 |
| US20150247204A1 (en) * | 2014-02-07 | 2015-09-03 | The General Hopital Corporation | Differential diagnosis of hepatic neoplasms |
| ES2951598T3 (es) | 2014-11-25 | 2023-10-23 | Curadigm Sas | Composición farmacéutica que combina al menos dos nanopartículas distintas y un compuesto farmacéutico, preparación y usos de los mismos |
| DK3223796T3 (da) | 2014-11-25 | 2021-09-27 | Curadigm Sas | Farmaceutiske sammensætninger, fremstilling og anvendelser deraf |
| KR102666251B1 (ko) | 2014-11-25 | 2024-05-27 | 큐라디즘 | 약학적 조성물, 이의 제조 및 용도 |
| WO2016083331A1 (en) | 2014-11-25 | 2016-06-02 | Nanobiotix | Pharmaceutical composition, preparation and uses thereof |
| US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
| US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
| MA43100A (fr) | 2015-05-28 | 2018-09-05 | Nanobiotix | Nanoparticules à utiliser en tant que vaccin thérapeutique |
| PL3998069T3 (pl) | 2015-06-29 | 2025-03-31 | Abraxis Bioscience, Llc | Nanocząsteczki zawierające syrolimus i albuminę do zastosowania w leczeniu nowotworów z komórek nabłonkowatych |
| BR112019006329A2 (pt) * | 2016-10-07 | 2019-06-25 | Abraxis Bioscience Llc | métodos de tratamento de câncer do trato biliar |
| WO2018081520A1 (en) | 2016-10-27 | 2018-05-03 | Zhuhai Beihai Biotech Co., Ltd. | Neutral ph compositions of docetaxel and human serum albumin |
| US10896749B2 (en) * | 2017-01-27 | 2021-01-19 | Shire Human Genetic Therapies, Inc. | Drug monitoring tool |
| CN107828887A (zh) * | 2017-10-12 | 2018-03-23 | 上海市东方医院 | Stmn1基因的用途 |
| IL277402B1 (en) | 2018-03-20 | 2026-04-01 | Abraxis Bioscience Llc | Methods for treating central nervous system disorders using administration of MTOR inhibitor nanoparticles and albumin |
| JP7832108B2 (ja) | 2019-10-28 | 2026-03-17 | アブラクシス バイオサイエンス， エルエルシー | アルブミンおよびラパマイシンの医薬組成物 |
| JP2024542042A (ja) * | 2021-10-26 | 2024-11-13 | リポジェムス・インターナショナル・エッセ・ピ・ア | 肝がん療法での薬物送達システムとしての微小断片化脂肪組織 |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9405798A (pt) | 1993-02-22 | 1995-12-12 | Vivorx Pharmaceuticals Inc | Métodos para liberação in vivo de material biológico e composições úteis dos mesmos |
| US6537579B1 (en) * | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
| US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| US5362478A (en) | 1993-03-26 | 1994-11-08 | Vivorx Pharmaceuticals, Inc. | Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell |
| US5916596A (en) | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US6753006B1 (en) | 1993-02-22 | 2004-06-22 | American Bioscience, Inc. | Paclitaxel-containing formulations |
| US6528067B1 (en) | 1993-02-22 | 2003-03-04 | American Bioscience, Inc. | Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof |
| US5439686A (en) | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
| US5997904A (en) | 1993-02-22 | 1999-12-07 | American Bioscience, Inc. | Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof |
| US5665382A (en) | 1993-02-22 | 1997-09-09 | Vivorx Pharmaceuticals, Inc. | Methods for the preparation of pharmaceutically active agents for in vivo delivery |
| US20030068362A1 (en) | 1993-02-22 | 2003-04-10 | American Bioscience, Inc. | Methods and formulations for the delivery of pharmacologically active agents |
| US6749868B1 (en) | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US5665383A (en) | 1993-02-22 | 1997-09-09 | Vivorx Pharmaceuticals, Inc. | Methods for the preparation of immunostimulating agents for in vivo delivery |
| US5650156A (en) | 1993-02-22 | 1997-07-22 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of nutriceuticals and compositions useful therefor |
| US6565842B1 (en) | 1995-06-07 | 2003-05-20 | American Bioscience, Inc. | Crosslinkable polypeptide compositions |
| US20070092563A1 (en) | 1996-10-01 | 2007-04-26 | Abraxis Bioscience, Inc. | Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| US20030199425A1 (en) | 1997-06-27 | 2003-10-23 | Desai Neil P. | Compositions and methods for treatment of hyperplasia |
| BRPI9810945B8 (pt) | 1997-06-27 | 2021-05-25 | Abraxis Bioscience Inc | formulações de agentes farmacológicos, métodos para sua preparação e métodos para uso das mesmas |
| US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| CA2369740A1 (en) | 1999-04-22 | 2000-11-02 | American Biosciences, Inc. | Long term administration of pharmacologically active agents |
| CA2684454A1 (en) | 1999-05-21 | 2000-11-18 | American Bioscience, Llc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| GB9920548D0 (en) | 1999-08-31 | 1999-11-03 | Rhone Poulenc Rorer Sa | Treatment of hepatocellular carcinoma |
| ITMI20001107A1 (it) | 2000-05-18 | 2001-11-18 | Acs Dobfar Spa | Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel |
| ITMI20020681A1 (it) | 2002-03-29 | 2003-09-29 | Acs Dobfar Spa | Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina |
| ITMI20020680A1 (it) | 2002-03-29 | 2003-09-29 | Acs Dobfar Spa | Composizione antitumorale migliorata a base di paclitaxel e metodo per il suo ottenimento |
| CN103405405A (zh) | 2002-12-09 | 2013-11-27 | 阿布拉西斯生物科学有限责任公司 | 组合物和传递药剂的方法 |
| PT1585548T (pt) | 2002-12-09 | 2018-10-17 | Abraxis Bioscience Llc | Composições e métodos de administração de agentes farmacológicos |
| US20070166388A1 (en) | 2005-02-18 | 2007-07-19 | Desai Neil P | Combinations and modes of administration of therapeutic agents and combination therapy |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| SI1853250T1 (sl) | 2005-02-18 | 2012-01-31 | Abraxis Bioscience Llc | Kombinacije in reĹľimi dajanja terapevtskih sredstev in kombinirana terapija |
| KR101420445B1 (ko) * | 2005-08-31 | 2014-07-16 | 아브락시스 바이오사이언스, 엘엘씨 | 수 난용성 제약학적 약제 및 항균제를 포함하는 조성물 |
| AU2006284657B2 (en) | 2005-08-31 | 2012-07-19 | Abraxis Bioscience, Llc | Compositions and methods for preparation of poorly water soluble drugs with increased stability |
| US20080045589A1 (en) * | 2006-05-26 | 2008-02-21 | Susan Kelley | Drug Combinations with Substituted Diaryl Ureas for the Treatment of Cancer |
| US20080280987A1 (en) | 2006-08-31 | 2008-11-13 | Desai Neil P | Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases |
| BRPI0622006A2 (pt) | 2006-08-31 | 2011-12-20 | Abraxis Bioscience Llc | usos de proteìna-veìculo e dìmero de colchicina ou tiocolchicina, forma unitária de dosagem, composição farmacêutica e kits |
| EP2076599A2 (en) * | 2006-09-19 | 2009-07-08 | Asuragen, Inc. | Mir-200 regulated genes and pathways as targets for therapeutic intervention |
| EP3470071A1 (en) | 2006-12-14 | 2019-04-17 | Abraxis BioScience, LLC | Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane |
| WO2008109163A1 (en) | 2007-03-07 | 2008-09-12 | Abraxis Bioscience, Llc. | Nanoparticle comprising rapamycin and albumin as anticancer agent |
| CA2683973A1 (en) | 2007-04-13 | 2008-10-23 | Abraxis Bioscience, Inc. | Sparc and methods of use thereof |
| US20100166869A1 (en) | 2007-05-03 | 2010-07-01 | Desai Neil P | Methods and compositions for treating pulmonary hypertension |
| JP5579057B2 (ja) | 2007-06-01 | 2014-08-27 | アブラクシス バイオサイエンス， エルエルシー | 再発性癌の処置のための方法および組成物 |
| MX2010011165A (es) | 2008-04-10 | 2011-02-22 | Abraxis Bioscience Llc | Composiciones de derivados de taxano hidrofobos y sus usos. |
| JP2011517683A (ja) | 2008-04-10 | 2011-06-16 | アブラクシス バイオサイエンス， エルエルシー | 疎水性タキサン誘導体の組成物およびその使用 |
| NZ593343A (en) | 2008-12-11 | 2013-04-26 | Abraxis Bioscience Llc | Combination cancer treatment conprising Abraxane and an inflamatory inhibitor |
| CN102427728A (zh) | 2009-03-13 | 2012-04-25 | 阿布拉科斯生物科学有限公司 | 用硫代秋水仙碱衍生物进行联合治疗 |
| EP2416650B1 (en) | 2009-04-10 | 2020-02-26 | Abraxis BioScience, LLC | Nanoparticle formulations and uses therof |
| HRP20192259T1 (hr) | 2009-04-15 | 2020-03-06 | Abraxis Bioscience, Llc | Pripravci nanočestica bez priona i metode njihove proizvodnje |
| PL2470173T3 (pl) | 2009-08-25 | 2016-11-30 | Leczenie skojarzone nanocząstkowymi kompozycjami taksanu i inhibitorów hedgehog | |
| CA3051495A1 (en) | 2010-03-26 | 2011-09-29 | Abraxis Bioscience, Llc | Use of nanoparticles comprising a taxane and albumin in the treatment of hepatocellular carcinoma |
| KR20130028727A (ko) | 2010-03-29 | 2013-03-19 | 아브락시스 바이오사이언스, 엘엘씨 | 치료제의 약물 전달 및 유효성 향상 방법 |
| NZ717490A (en) | 2010-03-29 | 2017-12-22 | Abraxis Bioscience Llc | Methods of treating cancer |
| WO2011153009A1 (en) | 2010-06-02 | 2011-12-08 | Abraxis Bioscience, Llc | Methods of treating bladder cancer |
| BR112012030909A2 (pt) | 2010-06-04 | 2020-08-18 | Abraxis Bioscience, Llc | métodos de tratamento de câncer pancreático |
| WO2011156119A1 (en) | 2010-06-07 | 2011-12-15 | Abraxis Bioscience, Llc | Combination therapy methods for treating proliferative diseases |
| JP6038123B2 (ja) | 2011-04-28 | 2016-12-07 | アブラクシス バイオサイエンス， エルエルシー | ナノ粒子組成物の脈管内送達およびそれらの使用 |
| JP6216721B2 (ja) | 2011-12-14 | 2017-10-18 | アブラクシス バイオサイエンス， エルエルシー | 粒子を凍結乾燥または凍結するためのポリマー賦形剤の使用 |
| US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
| US20140186447A1 (en) | 2012-12-28 | 2014-07-03 | Abraxis Bioscience, Llc | Nanoparticle compositions of albumin and paclitaxel |
| US20140199405A1 (en) | 2013-01-11 | 2014-07-17 | Abraxis Bioscience, Llc | Method for treating cancer based on mutation status of k-ras |
| US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| US20140199404A1 (en) | 2013-01-11 | 2014-07-17 | Abraxis Bioscience, Llc | Method for treating cancer based on level of a nucleoside transporter |
-
2011
- 2011-03-25 CA CA3051495A patent/CA3051495A1/en not_active Abandoned
- 2011-03-25 PT PT117603332T patent/PT2552438T/pt unknown
- 2011-03-25 KR KR1020127027815A patent/KR101786142B1/ko active Active
- 2011-03-25 ES ES14200645.1T patent/ES2675212T3/es active Active
- 2011-03-25 ES ES11760333.2T patent/ES2580135T3/es active Active
- 2011-03-25 MX MX2016015444A patent/MX359413B/es unknown
- 2011-03-25 CA CA2793536A patent/CA2793536C/en active Active
- 2011-03-25 AU AU2011230512A patent/AU2011230512B2/en active Active
- 2011-03-25 MX MX2012010936A patent/MX346861B/es active IP Right Grant
- 2011-03-25 HU HUE11760333A patent/HUE027749T2/en unknown
- 2011-03-25 EP EP11760333.2A patent/EP2552438B1/en active Active
- 2011-03-25 US US13/583,603 patent/US9370494B2/en active Active
- 2011-03-25 JP JP2013501523A patent/JP5847156B2/ja active Active
- 2011-03-25 HR HRP20160609TT patent/HRP20160609T1/hr unknown
- 2011-03-25 BR BR112012024349A patent/BR112012024349A2/pt not_active Application Discontinuation
- 2011-03-25 LT LTEP11760333.2T patent/LT2552438T/lt unknown
- 2011-03-25 EP EP14200645.1A patent/EP2898884B1/en active Active
- 2011-03-25 DK DK11760333.2T patent/DK2552438T3/en active
- 2011-03-25 NZ NZ602382A patent/NZ602382A/en unknown
- 2011-03-25 CN CN201180025949.1A patent/CN103052385B/zh active Active
- 2011-03-25 WO PCT/US2011/030037 patent/WO2011119988A1/en not_active Ceased
- 2011-03-25 PL PL11760333.2T patent/PL2552438T3/pl unknown
- 2011-03-25 CN CN201510242264.2A patent/CN104784121A/zh active Pending
- 2011-03-28 TW TW100110703A patent/TWI495467B/zh active
-
2012
- 2012-09-11 IL IL221886A patent/IL221886A/en active IP Right Grant
-
2013
- 2013-02-28 US US13/781,480 patent/US20140079787A1/en not_active Abandoned
-
2015
- 2015-04-28 JP JP2015091142A patent/JP2015134825A/ja active Pending
-
2016
- 2016-05-20 US US15/160,598 patent/US20160374952A1/en not_active Abandoned
- 2016-08-08 IL IL247171A patent/IL247171B/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013523656A5 (https=) | ||
| HRP20160609T1 (hr) | Postupci liječenja hepatocelularnog karcinoma | |
| JP2013503174A5 (https=) | ||
| JP2015134825A5 (https=) | ||
| Chen et al. | Autophagy and doxorubicin resistance in cancer | |
| JP2010514787A5 (https=) | ||
| JP2013527233A5 (https=) | ||
| Gauthier et al. | Role of sorafenib in the treatment of advanced hepatocellular carcinoma: An update | |
| RU2012156275A (ru) | Способ и лечение рака поджелудочной железы | |
| Provencio et al. | New molecular targeted therapies integrated with radiation therapy in lung cancer | |
| JP2010509331A5 (https=) | ||
| WO2007139930A3 (en) | Drug combinations with substituted diaryl ureas for the treatment of cancer | |
| JP2016512506A5 (https=) | ||
| JP2019529520A5 (https=) | ||
| Vokes et al. | PROCLAIM: A phase III study of pemetrexed, cisplatin, and radiation therapy followed by consolidation pemetrexed versus etoposide, cisplatin, and radiation therapy followed by consolidation cytotoxic chemotherapy of choice in locally advanced stage III non–small-cell lung cancer of other than predominantly squamous cell histology | |
| Brogdon et al. | Development of other microtubule-stabilizer families: the epothilones and their derivatives | |
| JP2016505018A5 (https=) | ||
| JP2016536352A5 (https=) | ||
| WO2007069272A3 (en) | Pharmaceutical composition comprising at least one anticancer drug and at least one polymer | |
| JP2019521180A5 (https=) | ||
| JP2012514021A5 (https=) | ||
| Kobayashi et al. | Effect of FOLFIRINOX as second-line chemotherapy for metastatic pancreatic cancer after gemcitabine-based chemotherapy failure | |
| Lee et al. | Paclitaxel-loaded polymeric micelle (230 mg/m2) and cisplatin (60 mg/m2) vs. paclitaxel (175 mg/m2) and cisplatin (60 mg/m2) in advanced Non–small-cell lung cancer: a multicenter randomized phase IIB trial | |
| Awada et al. | Phase I trial to investigate the safety, pharmacokinetics and efficacy of sorafenib combined with docetaxel in patients with advanced refractory solid tumours | |
| JP2018536655A5 (https=) |